Jonathan M Brotchie

Jonathan M Brotchie

UNVERIFIED PROFILE

Are you Jonathan M Brotchie?   Register this Author

Register author
Jonathan M Brotchie

Jonathan M Brotchie

Publications by authors named "Jonathan M Brotchie"

Are you Jonathan M Brotchie?   Register this Author

100Publications

1527Reads

14Profile Views

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein.

Acta Neuropathol Commun 2020 Feb 14;8(1):17. Epub 2020 Feb 14.

Krembil Research Institute, Toronto Western Hospital, University Health Network, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40478-020-0894-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023783PMC
February 2020

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.

J Pharmacol Exp Ther 2019 06 27;369(3):364-374. Epub 2019 Mar 27.

Atuka Inc., Toronto, Ontario, Canada (T.H.J., P.R., M.P.H., J.S., J.M.B., J.B.K.); Junaxo Inc., Toronto, Ontario, Canada (P.A.H.); and Krembil Research Institute, University Health Network, Toronto, Ontario, Canada (P.A.H., T.H.J., P.R., M.P.H., J.M.B., J.B.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.118.255695DOI Listing
June 2019

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.

Sci Rep 2019 Jun 10;9(1):8362. Epub 2019 Jun 10.

Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-42847-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557812PMC
June 2019

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Neuropharmacology 2019 03 1;147:11-27. Epub 2018 Jun 1.

Krembil Research Institute, University Health Network, Toronto, ON, Canada; Atuka Inc., Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2018.05.035DOI Listing
March 2019

Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Eur J Neurosci 2019 Feb 15;49(3):399-409. Epub 2018 Nov 15.

Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejn.14173DOI Listing
February 2019

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

J Pharmacol Exp Ther 2018 11 7;367(2):373-381. Epub 2018 Aug 7.

Adamas Pharmaceuticals, Inc., Emeryville, California (E.F.B., C.B., J.D.S.H., J.T.N.); Atuka Inc, Toronto, Ontario, Canada (T.H.J., M.P.H., P.A.H., J.M.B.); Krembil Research Institute, University Health Network, Toronto, Ontario, Canada (T.H.J., S.H.F., J.M.B.); and Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, Ontario, Canada (S.H.F.)

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.118.24
Publisher Site
http://dx.doi.org/10.1124/jpet.118.247650DOI Listing
November 2018

Non-steric-zipper models for pathogenic α-synuclein conformers.

APL Bioeng 2018 Jun 1;2(2):026105. Epub 2018 May 1.

Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1063/1.5023460DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481714PMC
June 2018

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Neuropharmacology 2018 03 29;131:116-127. Epub 2017 Nov 29.

Atuka Inc.,Toronto, ON, Canada; Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2017.11.046DOI Listing
March 2018

Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"

Ann Neurol 2017 11 26;82(5):856. Epub 2017 Oct 26.

Department of Neurology, University Hospital of Würzburg, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25066DOI Listing
November 2017

Animal models of α-synucleinopathy for Parkinson disease drug development.

Nat Rev Neurosci 2017 Sep 13;18(9):515-529. Epub 2017 Jul 13.

Krembil Research Institute, Toronto Western Hospital, University Health Network, 60 Leonard Ave, Toronto, Ontario M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrn.2017.75DOI Listing
September 2017

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Trends Neurosci 2016 11 21;39(11):750-762. Epub 2016 Oct 21.

Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, ONT, Canada; The Krembil Institute, University Health Network, Toronto, ONT, Canada; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ONT, Canada; Department of Medicine, University of Toronto, Toronto, ONT, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tins.2016.09.003DOI Listing
November 2016

Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.

Acta Neuropathol Commun 2016 10 3;4(1):108. Epub 2016 Oct 3.

Department of Neurology, University Hospital of Würzburg, University of Würzburg, Josef-Schneider-Strasse 11, 97080, Würzburg, Germany.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048687PMC
http://dx.doi.org/10.1186/s40478-016-0375-7DOI Listing
October 2016

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Neuropharmacology 2015 Oct 10;97:306-11. Epub 2015 Jun 10.

Toronto Western Research Institute, University Health Network, 60 Leonard Ave., Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2015.05.033DOI Listing
October 2015

The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent.

Eur J Pharmacol 2015 Oct 8;764:379-84. Epub 2015 Jul 8.

Departments of Pharmacology and Psychiatry, University of Toronto, Toronto, ON, Canada M5S 1A8; Centre of Addiction and Mental Health, Toronto, ON, Canada M5T 1R8. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2015.07.013DOI Listing
October 2015

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

Synapse 2015 Mar;69(3):99-102

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada; Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/syn.21801DOI Listing
March 2015

Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats.

Exp Neurol 2015 Mar 23;265:160-70. Epub 2015 Jan 23.

Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, NY USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2015.01.004DOI Listing
March 2015

Monoamine reuptake inhibitors in Parkinson's disease.

Parkinsons Dis 2015 25;2015:609428. Epub 2015 Feb 25.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/609428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355567PMC
March 2015

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Behav Pharmacol 2015 Feb;26(1-2):101-8

aToronto Western Research Institute bDivision of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/behaviouralpharm/2015/02000/L_7
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/FBP.0000000000000096DOI Listing
February 2015

Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Mov Disord 2015 Feb 21;30(2):150-9. Epub 2015 Jan 21.

Department of Neurology, National Parkinson Foundation International Centre of Excellence, King's College Hospital, King's Health Partners, London, UK.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077247PMC
http://dx.doi.org/10.1002/mds.26099DOI Listing
February 2015

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.

Neurobiol Dis 2014 Nov 27;71:334-44. Epub 2014 Aug 27.

Centre for Neurobiology of Stress, Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2014.08.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486078PMC
November 2014

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Neuropharmacology 2013 Oct 14;73:337-47. Epub 2013 Jun 14.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2013.06.005DOI Listing
October 2013

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Mov Disord 2013 Oct 3;28(12):1675-82. Epub 2013 Sep 3.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama-Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25625DOI Listing
October 2013

The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.

Prog Neuropsychopharmacol Biol Psychiatry 2013 Jun 7;43:151-6. Epub 2013 Jan 7.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02785846120031
Publisher Site
http://dx.doi.org/10.1016/j.pnpbp.2012.12.008DOI Listing
June 2013

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Parkinsonism Relat Disord 2013 Feb 14;19(2):260-4. Epub 2012 Aug 14.

Division of Brain, Imaging & Behaviour, Systems Neuroscience, Toronto Western Research Institute, 399 Bathurst Street, MP-12-303, Toronto, ON M5T2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2012.07.001DOI Listing
February 2013

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.

Mov Disord 2013 Feb 5;28(2):131-44. Epub 2012 Dec 5.

Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25273DOI Listing
February 2013

Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat.

J Neurophysiol 2013 Jan 17;109(2):363-74. Epub 2012 Oct 17.

Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, NY 12208, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/jn.00311.2012DOI Listing
January 2013

Selective preservation of MeCP2 in catecholaminergic cells is sufficient to improve the behavioral phenotype of male and female Mecp2-deficient mice.

Hum Mol Genet 2013 Jan 16;22(2):358-71. Epub 2012 Oct 16.

Division of Genetics and Development, Toronto Western Research Institute, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/hmg/dds433DOI Listing
January 2013

Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat.

Eur J Neurosci 2013 Jan 4;37(2):231-41. Epub 2012 Nov 4.

Center for Neuropharmacology and Neuroscience, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejn.12040DOI Listing
January 2013

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Pharmacol Rev 2013 Jan 10;65(1):171-222. Epub 2013 Jan 10.

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/pr.111.005678DOI Listing
January 2013

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Neuropharmacology 2012 Oct 18;63(5):829-36. Epub 2012 Jun 18.

Toronto Western Research Institute, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2012.06.012DOI Listing
October 2012

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

J Pharmacol Exp Ther 2012 Aug 22;342(2):576-85. Epub 2012 May 22.

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.112.195693DOI Listing
August 2012

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.

Mov Disord 2012 May 14;27(6):735-42. Epub 2012 Mar 14.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.24964DOI Listing
May 2012

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

Neurobiol Aging 2012 Jan 18;33(1):194.e5-15. Epub 2010 Jun 18.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2010.04.035DOI Listing
January 2012

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

Neurobiol Aging 2012 Jan 3;33(1):207.e9-19. Epub 2010 Nov 3.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2010.09.011DOI Listing
January 2012

Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

J Mol Neurosci 2012 Jan 12;46(1):145-52. Epub 2011 May 12.

Department of Pharmacology, Faculty of Pharmacy, University of Aleppo, P.O. Box. 8119, Aleppo, Syria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12031-011-9539-xDOI Listing
January 2012

Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?

J Pharmacol Exp Ther 2011 Oct 22;339(1):2-8. Epub 2011 Jul 22.

Toronto Western Research Institute, MCL 11-419, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.111.184093DOI Listing
October 2011

5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms.

Exp Neurol 2011 Oct 30;231(2):195-8. Epub 2011 Jul 30.

Toronto Western Research Institute, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2011.07.006DOI Listing
October 2011

The serotonergic system in Parkinson's disease.

Prog Neurobiol 2011 Oct 22;95(2):163-212. Epub 2011 Aug 22.

Toronto Western Research Institute, MCL 11-419, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pneurobio.2011.08.004DOI Listing
October 2011

Pros and cons of a prion-like pathogenesis in Parkinson's disease.

BMC Neurol 2011 Jun 20;11:74. Epub 2011 Jun 20.

Department of Neurology, Goethe University, Frankfurt/Main, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2377-11-74DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128002PMC
June 2011

Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains.

J Neurosci Methods 2011 Apr 23;197(2):193-208. Epub 2011 Feb 23.

Centre for Neurobiology of Stress, Dept Biological Sciences, University of Toronto at Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneumeth.2011.02.012DOI Listing
April 2011

Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism.

Neurobiol Dis 2011 Mar 21;41(3):591-604. Epub 2010 Oct 21.

Centre for Neurobiology of Stress, Dept. of Biological Sciences, University of Toronto, Scarborough, 1265 Military Trail, Toronto, ON, Canada M1C 1A4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2010.10.013DOI Listing
March 2011

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.

Prog Brain Res 2010 ;184:133-57

Division of Neurology, University of Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0079-6123(10)84007-5DOI Listing
January 2011

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.

Mov Disord 2010 Oct;25(13):2084-93

Division of Brain, Imaging, and Behaviour-Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23172DOI Listing
October 2010

Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.

Neurosci Res 2010 Sep 11;68(1):44-50. Epub 2010 Jun 11.

Department of Pharmacology, Faculty of Pharmacy, University of Aleppo, Aleppo, Syria P.O. Box 8119, Syrian Arab Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neures.2010.06.003DOI Listing
September 2010

Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors.

Neurosci Res 2010 Jul 17;67(3):245-9. Epub 2010 Mar 17.

Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester M13 9PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neures.2010.03.008DOI Listing
July 2010

Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

Mov Disord 2010 Jul;25(10):1379-90

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23069DOI Listing
July 2010

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations.

Mov Disord 2010 Jul;25(10):1399-408

Division of Brain Imaging & Behaviour Systems - Neuroscience, Toronto Western Research Institute,Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23083DOI Listing
July 2010

Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.

Synapse 2010 Feb;64(2):177-80

Greater Manchester Neurosciences Centre, Salford Royal Hospital, Stott Lane, Salford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/syn.20739DOI Listing
February 2010

Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride.

J Pharm Sci 2010 Jan;99(1):234-45

School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, Crawley, WA 6009, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.21823DOI Listing
January 2010

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

Can J Neurol Sci 2010 Jan;37(1):86-95

Division of Neurology, Toronto Western Research Institute, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100009707DOI Listing
January 2010

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Neurobiol Dis 2009 Aug 9;35(2):184-92. Epub 2008 Dec 9.

Toronto Western Research Institute, 399 Bathurst Street, MC11-419, Toronto, Ontario M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2008.11.010DOI Listing
August 2009

Serotonin and Parkinson's disease: On movement, mood, and madness.

Mov Disord 2009 Jul;24(9):1255-66

Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.22473DOI Listing
July 2009

New insights into the organization of the basal ganglia.

Curr Neurol Neurosci Rep 2009 Jul;9(4):298-304

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-009-0045-2DOI Listing
July 2009

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

Prog Brain Res 2008 ;172:479-94

Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0079-6123(08)00923-0DOI Listing
January 2009

Non-dopaminergic treatments in development for Parkinson's disease.

Lancet Neurol 2008 Oct;7(10):927-38

Movement Disorders Clinic, Division of Neurology, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(08)70214-XDOI Listing
October 2008

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.

Neuropharmacology 2008 Sep 27;55(4):483-90. Epub 2008 Jun 27.

Laboratoire de Neurobiologie de la Cognition, CNRS UMR 6155, Aix-Marseille Université, Case C, 3 Place Victor Hugo, 13331 Marseille Cedex 3, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2008.06.038DOI Listing
September 2008

Striatal histone modifications in models of levodopa-induced dyskinesia.

J Neurochem 2008 Jul 1;106(1):486-94. Epub 2008 Jul 1.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, AL 35294-0017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1471-4159.2008.05417.xDOI Listing
July 2008

Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice.

Hum Mol Genet 2008 May 25;17(10):1386-96. Epub 2008 Jan 25.

Division of Genetics and Development, Toronto Western Research Institute, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://hmg.oxfordjournals.org/content/17/10/1386.full.pdf
Web Search
http://www.hmg.oxfordjournals.org/cgi/doi/10.1093/hmg/ddn026
Publisher Site
http://dx.doi.org/10.1093/hmg/ddn026DOI Listing
May 2008

Levodopa-induced dyskinesias.

Mov Disord 2007 Jul;22(10):1379-89; quiz 1523

Department of Neurological Sciences University of Rome La Sapienza, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.21475DOI Listing
July 2007

Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.

Exp Neurol 2006 Nov 30;202(1):85-92. Epub 2006 Jun 30.

Toronto Western Research Institute, 399 Bathurst Street, MC11-419, Toronto, Ontario, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S001448860600303
Publisher Site
http://dx.doi.org/10.1016/j.expneurol.2006.05.016DOI Listing
November 2006

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Mov Disord 2006 Nov;21(11):1879-91

Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.21073DOI Listing
November 2006

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.

Mov Disord 2006 Oct;21(10):1578-94

Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.20936DOI Listing
October 2006

A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.

Neuropharmacology 2006 Sep 30;51(3):557-65. Epub 2006 Jun 30.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, MC 11-419, Toronto, Ontario, M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2006.04.016DOI Listing
September 2006

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Mov Disord 2006 Jun;21(6):839-46

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.20828DOI Listing
June 2006

Drugs in development for Parkinson's disease: an update.

Curr Opin Investig Drugs 2006 Jan;7(1):25-32

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, MC 11-419, Toronto, ON M5T 2S8, Canada.

View Article

Download full-text PDF

Source
January 2006

Advances in the delivery of treatments for Parkinson's disease.

Expert Opin Drug Deliv 2005 Nov;2(6):1059-73

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425247.2.6.1059DOI Listing
November 2005

Nondopaminergic mechanisms in levodopa-induced dyskinesia.

Mov Disord 2005 Aug;20(8):919-31

Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.20612DOI Listing
August 2005

A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.

FASEB J 2005 Jul 13;19(9):1140-2. Epub 2005 May 13.

Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, NA, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.04-3010fjeDOI Listing
July 2005

Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus.

Exp Neurol 2005 Jul;194(1):284-7

Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, MC 11-419, Toronto, Ontario, Canada M5T 258.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2005.02.012DOI Listing
July 2005

MPTP-induced models of Parkinson's disease in mice and non-human primates.

Curr Protoc Pharmacol 2005 Jul;Chapter 5:Unit5.42

Toronto Western Research Institute, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/0471141755.ph0542s29DOI Listing
July 2005

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Exp Neurol 2005 Feb;191(2):243-50

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2004.10.002DOI Listing
February 2005

Drugs in development for Parkinson's disease.

Curr Opin Investig Drugs 2004 Jul;5(7):720-6

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
July 2004